Metroid Prime Trilogy Switch Is Complete, But Nintendo Is Holding It As Per Reports
Metroid Prime Trilogy might not be coming soon.
Metroid Prime Trilogy is one of the most awaited games on the Nintendo Switch, and we have got some exciting information about it. Over the years, the franchise has built quite a loyal fanbase, with the first game releasing back in 1986.
- MORE: Metroid Dread Comes to Life As Pixel Art by Star Renegades Artist
We do know that a Metroid Prime sequel is in development. It was announced back in E3 2017 but we barely heard anything about it after that. A subsequent announcement followed in January 2019, where it was stated that the game’s release was delayed. That being said, the fact that the game’s development was shifted to the original studio was something that the community was quite excited about.
There have been rumors of a Metroid Prime Trilogy port for Nintendo Switch, but we didn’t receive any official information yet. However, we have received some credible information today.
Metroid Prime Trilogy Switch Is Complete, But Nintendo Is Holding It
According to prominent journalist Jeff Grubb, the Metroid Prime Trilogy for Switch is complete. This was revealed during the third Episode of Grubbsnax. However, Nintendo has planned not to release it and hold it for now. The reason for that is that it will be a marketing beat for the release of Metroid Prime 4.
It is stated that the Metroid Prime Trilogy will be releasing closer to Metroid Prime 4, but this is purely based on speculation. Nintendo is known to hold games like these in the past, as was the case with Pikmin 3 Deluxe, which was reported by Grubb earlier as well.
While this might disappoint many fans out there, it does make sense from Nintendo’s point of view. The fact that Metroid Prime 4 has been in development for so long might have reduced the buzz around it, and the release of the Trilogy could be the perfect way to build up the hype once again and remind players about why the Metroid Prime franchise is critically acclaimed.